STUDY PARTICIPANTS NEEDED:
NON-MEDICATION WEIGHT LOSS RESEARCH STUDY FOR PEOPLE WITH TYPE 2 DIABETES: Effects on glycemic control and weight of a modified commercial weight control program for people with type 2 diabetes
The purpose of this study to evaluate the effectiveness of a weight loss program modified for people with type 2 diabetes. No medication is given to participants in this study. To qualify, you must have type 2 diabetes, be between the ages of 19 and 70 years, overweight, not have significant illness or disease (such as heart disease), not be taking any medications for weight loss, and meet other criteria. Qualified participants will be asked to attend 6 assessment visits, and will receive different degrees and types of weight management counseling, as well as medical exams, lab work, and weight monitoring. This study requires a commitment of a little more than 52 weeks. Please call one of the following numbers and leave a voice message requesting more detailed information: 205-996-4015 or 205-975-8217.
The purpose of this study is to find out why some individuals are insulin resistant, while other individuals are insulin sensitive. Insulin moves glucose (sugar) from the bloodstream into the muscle, where it is metabolized (used by the body). In many individuals, this process is impaired; the body tissue resistance to the effects of insulin increases the risk of developing diabetes, hypertension (high blood pressure), heart disease, and stroke (associated with hardening of the arteries). The investigator hopes to better understand the actual biochemical cause of this insulin resistance, since this knowledge could be used to develop improved methods of treatment or prevention. You will receive laboratory testing, metabolic testing & physical exam, all at no charge to you. We are recruiting both healthy volunteers ages 21-59 and those with Type 2 Diabetes. To inquire, please contact Sandra at 205-996-4020 or Dana at 205-996-4015.
IDENTIFICATION OF MUSCLE SPECIFIC BIOMARKERS OF FATTY ACID BETA-OXIDATION STUDY
The investigator hopes to identify clinically–relevant biomarkers of metabolism (used in muscle-fat) to help identify at-risk persons, determine etiology of disease and ultimately use this knowledge to help develop improved methods of treatment or prevention. We are recruiting African American females for this study, ages 21 to 59 with a body mass index (BMI) between 27-42. The study will provide dietary food for one week and includes testing, metabolic testing & physical exam, all at no charge to you. To inquire, please contact Sandra at 205-996-4020 or Dana at 205-996-4015.
MECHANISMS OF HUMAN INSULIN RESISTANCE: ROLE OF LIPID METABOLISM
The goal of the study is to apply state-of-the-art metabolomics technologies, to determine the Effects of Weight Loss on Mechanisms Regulating Insulin Sensitivity (focus on adipose tissue inflammation, lipid metabolism as probed using metabolomic profiles, and GI microflora. Healthy volunteers and Type 2 Diabetics needed for dietary weight loss study. Must be 21-59 yrs. old, and have a BMI 30-45 (moderately overweight). Physical exam, lab results and food to be provided. To inquire, please contact Sandra at 205-996-4020 or Dana at 205-996-4015.
The purpose of this study is to see the effects of different macronutrient profiles on weightloss in overweight girls. We seek to evaluate the effects of different weightloss diets on bone and fat mass as well as metabolism. Overweight girls ages seven to eleven years are invited to participate. All food will be provided for sixteen weeks. This study requires consumption of only included foods over the duration of the study. In addition, for assessment of metabolic parameters, meal tests with blood draws are necessary. Compensation. To inquire, please contact Krista or Annie at 205-975-4316.
The purpose of this study is to examine the contributions of genetic and environmental factors on racial differences in the risk for diabetes.
EXSCEL STUDY: A Randomized, Placebo Controlled Trial to Evaluate Cardiovascular Outcomes after the Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus.
The primary study objective is to compare the impact of including Exenatide Once Weekly as part of usual care versus usual care without Exenatide Once Weekly on major cardiovascular outcomes. Phase 3b/4 eligibility: Adults with type 2 diabetes with a hemoglobin A1c of 7 or greater but equal to or less than 10 receiving a stable (at least 3 month) dose of 0-3 medications for diabetes who have a history of cardiovascular disease.